New Blood Pressure Treatment Shows Promise for Resistant Hypertension Patients
A new medication, baxdrostat, has demonstrated significant efficacy in reducing blood pressure among patients whose hypertension remains uncontrolled despite existing treatments. This development emerged from a Phase III clinical trial led by Professor Bryan Williams at the UCL Institute of Cardiovascular Science. The trial, known as BaxHTN, involved nearly 800 patients across 214 clinics worldwide and was funded by AstraZeneca. The results, presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine, revealed that patients taking baxdrostat experienced an average blood pressure reduction of 9 to 10 mmHg more than those on a placebo. Approximately 40% of these patients achieved healthy blood pressure levels, compared to less than 20% in the placebo group. Baxdrostat works by inhibiting the production of aldosterone, a hormone that regulates salt and water levels, thereby addressing a key factor in hypertension. 
